

15% of premature births <sup>1</sup>



Multiple guidelines recommend the use of PIGF and sFLT-1 for the screening and aid in diagnosis of pre-eclampsia (ISUOG, FIGO, ISSHP, NICE,...). View these guidelines:



- 3. Milne et al. (2009) BMJ, 339:b3129
- 4. Health Belgium, 2019

- 7. Rolnik et al. (2017). N Engl J Med, 377(7):613-622

- 10. Verlohren et al. (2014). Hypertension, 63: 346-352



More info? Mail to vilvoorde.medicalvalue@roche.com

Roche Diagnostics Belgium Berkenlaan 8A 1831 Diegem

Tency I. et al. Perinatal referral in Belgium. FOD, 2007 2. Verlohren S. et al. (2010). Am J. Obstet Gynecol, 202 (161): e1-11

5. O'Gorman et al. (2016). Am J. Obstet Gynecol, 214: 103.e1-12 6. O'Gorman N et al. (2017). Ultrasound Obstet Gynecol, 49: 756–760 8. Poon L.C. et al, Int J Gynecol Obstet 2019;145(Suppl.1): 1-33 9. Zeisler H. et al. (2016). N Engl J Med, 374: 13-22

- 11. Lanssens, D. et al. (2017). JMIR mHealth and uHealth, 5(3), e25
- 12. KCE Report 232Cs. Caring for mothers and newborns after uncomplicated delivery: towards integrated postnatal care
- 13. Statbel (2019, February 26). Feto-infant mortality Retrieved March 12, 2019, from: https://statbel.fgov.be/en/themes/ population/feto-infant-mortality
- 14. Information received by request to FPS Health
- 15. Wright, D. et al. (2018). Am J Obstet Gynecol, 218(6), 612-e1
- 16. Terugbetalingsdossier Elecsys® sFLT-1-PIGF immunoassay ratio. Submitted to RIZIV/INAMI November 2019



## **Pre-eclampsia** *Clinical and economic value of testing*

## 1<sup>st</sup> trimester

screening



Treatment with low dose aspirin can decrease the incidence of preterm pre-eclampsia by



150 mg aspirin from week 11-14 until week 36

34 weeks to end of pregnancy

## **2<sup>nd</sup> and 3<sup>rd</sup> trimester**

the Elecsys<sup>®</sup> immunoassay sFLT-1/PlGF ratio







97.9% 99.3% rules out

within 1 week

rules out within 2 weeks

rules out within 3 weeks

95.7%

rules out within 4 weeks

94.3%

2<sup>nd</sup> and 3<sup>rd</sup> trimester



In practice: blood sample on serum, in women with signs and symptoms of pre-eclampsia, between week 20-37, ratio sFLT/PIGF will define the risk.

## **Clinical and economic benefits of testing**





Decrease in: c-sections <sup>11, 12</sup>

- neonatal deaths and stillbirths <sup>13, 14</sup>
- NICU admissions <sup>15</sup>
- NICU length of stay <sup>14</sup>



Savings and improvements of health outcomes for mother and baby with no net increase in the health costs 16



Accurate hospital admission



Aid in delivery decisions



15%

reduction of unnecessary hospitalizations 16 Savings per patient <sup>11</sup>

•

**692 €**